RESULTS The instruments most frequently used were single-item VAS and Biberoglu and Behrman pain score , while multidimensional inventories were used in few studies .
The results of clinical studies in CPP are more frequently based on one-dimensional measurements .
RATIONALE Many types of  pain assessment are available to research ers carrying out clinical trials in chronic pelvic pain ( CPP ) , ranging from a single-item scale to multidimensional inventories .
AIM Our objective was to investigate which assessment s of pain are more commonly used in clinical trials on CPP .
Maintenance therapy with dienogest following gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain.
OBJECTIVE To examine whether long-term administration of dienogest following gonadotropin-releasing hormone agonist ( GnRH-a ) therapy would prolong the relief of pelvic pain while reducing the amount of irregular uterine bleeding . STUDY DESIGN This was a prospect i ve , non-r and omized clinical trial . Among the patients suffering from chronic pelvic pain associated with recurrent endometriosis , Group G ( n=38 ) received GnRH-a for 4 - 6 months and then dienogest ( 1 mg/day ) for 12 months . The dose of dienogest was increased to 1.5 or 2 mg/day when a patient had uncontrollable uterine bleeding { n=15 (39%)}. Group D ( n=33 ) received only dienogest ( 2 mg/day ) for 12 months . Pelvic pain was assessed using a visual analog scale ( VAS ) . Uterine bleeding was semi-quantified using a pictorial blood loss assessment chart ( PBAC ) . RESULTS In Group G , GnRH-a significantly reduced the VAS score for pelvic pain , and alleviation was maintained during the 12-month therapy with dienogest . There was no significant difference in pain reduction between Group G and Group D. The PBAC score during the first 6 months on dienogest was significantly smaller in Group G than in Group D. CONCLUSION Treatment with a GnRH-a followed by long-term dienogest therapy maintains the relief of endometriosis-associated pelvic pain achieved with GnRH-a therapy for at least 12 months . This regimen reduces the amount of irregular uterine bleeding that often occurs during the early phase of dienogest therapy
RESULTS The instruments most frequently used were single-item VAS and Biberoglu and Behrman pain score , while multidimensional inventories were used in few studies .
The results of clinical studies in CPP are more frequently based on one-dimensional measurements .
RATIONALE Many types of  pain assessment are available to research ers carrying out clinical trials in chronic pelvic pain ( CPP ) , ranging from a single-item scale to multidimensional inventories .
AIM Our objective was to investigate which assessment s of pain are more commonly used in clinical trials on CPP .